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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S200“zone of helpfulness”, and personality style and how it
relates to communication. The training will be offered
utilizing a combination of education strategies including
web-based video and return demonstration with clinical
managers.
Evaluation: The trainingwill be evaluated using pre and post
measures of BMT nurses’ conﬁdence and conﬁdence in
providing psychosocial support to patients and families. Data
will be collected at baseline and at three and six months post
communication skills training.302
The Role of Occupational Therapy and Its Impact on
Quality of Life for the Pediatric Stem Cell Recipient
Alisha Nicole Pratt 1, Jill Marie Bakker 2. 1 OTPTTR, Cincinnati
Childrens Hospital Medical Center, Cincinnati, OH; 2 OT/PT/TR,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Clinical Question (in PICO format)
P (Population/Problem) Among school aged children (3-18
years of age) receiving a stem cell transplant (SCT)*
I (Intervention) Does occupational therapy intervention(s)
C (Comparison)
O (Outcome) Limit the negative affect of SCT on a patient’s
quality of life?
Target Population for the Recommendation (Inclusion /
Exclusion Criteria for the recommendation)
Preschool (3 years) to young adult (18 years) who are
admitted to an inpatient unit to undergo SCT in the protected
environment
Background / Purpose of BESt Development
SCT is a highly risky and aggressive therapeutic approach for
an assortment of formerly incurable malignancies, hemato-
logical disorders, genetic disorders, and metabolic storage
diseases that have evolved dramatically in the past 25 years,
advancing at a rapid pace as scientiﬁc discoveries are trans-
formed into pediatric clinical settings (Tanzi 2011 [1b]).
Throughout the evidence, it is understood that there are
three phases of SCT, which consist of pre-transplant, inpa-
tient hospitalization and post-transplant. This review focuses
on the acute, inpatient phase of SCT, including when the
patient is hospitalized in the protected environment (PE).
Evidence was reviewed with the objectives to delineate the
roles and responsibilities of the OT during the inpatient
phase of SCT, while also improving understanding of how the
role of OT can impact HRQOL.303
Determinants of Early and Late Transfusion Burden after
Hematopoietic Stem Cell Transplantation (HSCT): An
Analysis of 174 Transplant Recipients from a Single Center
Duncan Purtill 1, Annette Le Viellez 2, Julian P. Cooney 3,
Richard Herrmann 4, Matthew Wright 4, Paul Cannell 5.
1 Haematology Department, Royal Perth Hospital, Perth,
Australia; 2 Transfusion Laboratory, Royal Perth Hospital, Perth,
Australia; 3 Royal Perth Hospital Hem Dept, Perth, Australia;Transfusions between D0-D30
N patients
Disease stage: early vs intermediate vs advanced 42 vs 25 vs 106
Donor: ABO identical vs minor vs major incompatible 98 vs 33
vs 43
Donor: matched related vs unrelated 82 vs 90
Stem cell source: peripheral blood vs marrow vs cord blood 153 vs 14
vs 74 Department of Haematology, Royal Perth Hospital, Perth,
Australia; 5 Haematology, Royal Perth Hospital, Perth, Australia
Aim: Transfusion burden after HSCT in the modern era may
differ from that reported in the early literature regarding
bone marrow transplantation. We sought to quantify the red
cell (RC) and platelet transfusion burden associated with
HSCT at our center and to identify factors associated with
increased transfusions after transplant.
Methods: Patients were included who underwent ﬁrst
allogeneic HSCT at our center from 01/2004-12/2011. The
cumulative number of RC and platelet transfusions for each
patient was recorded at days 30, 90 and 365 post-transplant.
Products were transfused according to clinical need, usually
to maintain hemoglobin >80mg/dL and platelets >10x10e6/
L. Single donor apheresis platelets were used. Donor-recip-
ient pairs were ABO-identical, minor incompatible (donor
antibodies to recipient red cell RC) or major incompatible
(recipient antibodies to donor RC).
Results: 174 patients underwent HSCT for acute leukemia
(47%), other hematological malignancy (44%) or other diag-
nosis (3%) at amedian age of 42 years. Conditioning regimens
were myeloablative in 138 (80%) and reduced intensity in 34
(20%). A median of 12 (range 2-117) ABO group and antibody
screen assays were performed per patient between D0-D365.
All patients received at least one unit of either RC or platelets.
The median number of both RC and platelet units transfused
between D0-D30 was 4 each (range: 0-20 and 0-32 respec-
tively) and this was associated with patient and transplant
characteristics (Table). Post-transplant transfusions were not
inﬂuenced by recipient age, sex or conditioning regimen. Of
162 patients alive at day 31, 45 (28%) received RC and 37
(23%) platelet transfusions between D31-D90. Cord blood
recipients and those who developed grade 2-4 acute GVHD
were more likely to receive both RC (p ¼ 0.03 & p ¼ 0.01,
respectively) and platelets (p ¼ 0.005 & p ¼ 0.01) during this
period. After D90, relapse prior to D365 was the only factor
inﬂuencing both RC and platelet transfusions (p < 0.001 for
both).
Conclusion: The overall transfusion burden after allogeneic
HSCT at our center was lower than we expected. Patients
with advanced malignancies, ABO incompatible donors, and
unrelated or cord blood donors required more transfusions
early post-transplant, while GVHD and relapse were associ-
ated with transfusion after D30. These ﬁndings will inform
our clinical practice and assist the transfusion laboratory to
optimize cost-effectiveness and efﬁciency.304
Effects of Calcineurin Inhibitors on Urinary Sodium
Excretion Early after Allogenic Hematopoietic Stem Cell
Transplantation
Masuho Saburi, Takehiko Mori, Jun Kato, Yuya Koda,
Sumiko Kohashi, Shinichiro Okamoto. Division of Hematology,
Keio University School of Medicine, Tokyo, JapanRed cells (median units) P value Platelets (median units) P value
2 vs 5.5 vs 4 0.08 3 vs 4 vs 5 0.02
4 vs 6 vs 6 <0.001 4 vs 6 vs 4 0.15
4 vs 4.5 0.05 3 vs 5 0.003
4 vs 4 vs 11 0.003 4 vs 7
vs 16
<0.001
